Barclays’s Monopar Therapeutics MNPR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$151K Sell
1,893
-3,940
-68% -$423K ﹤0.01% 4123
2026
Q2
$540K Sell
5,833
-19,102
-77% -$1.18M ﹤0.01% 3169
2026
Q1
$1.37M Buy
24,935
+4,690
+23% +$283K ﹤0.01% 2569
2025
Q4
$1.32M Buy
20,245
+5,163
+34% +$422K ﹤0.01% 3243
2025
Q3
$1.23M Buy
15,082
+7,797
+107% +$349K ﹤0.01% 3242
2025
Q2
$261K Buy
7,285
+7,273
+60,608% +$264K ﹤0.01% 4117
2025
Q1
$437 Buy
+12
New +$432 ﹤0.01% 5087

Other funds holding MNPR

Barclays's MNPR Position: Q3 2026 in Review

Barclays reduced its Monopar Therapeutics (MNPR) stake by 68% in Q3 2026, selling an estimated $423K and leaving 1,893 shares worth $151K. The position accounts for ﹤0.01% of the portfolio, ranked #4123.

Barclays first reported a position in MNPR in Q1 2025 and has held it in 7 quarters since. The position peaked at $1.37M in Q1 2026. 106 funds tracked by Wall St. Rank hold MNPR as of Q3 2026.

  • Barclays held 1,893 shares of Monopar Therapeutics worth $151K as of Q3 2026.
  • Barclays sold 3,940 Monopar Therapeutics shares in Q3 2026, an estimated $423K.
  • Monopar Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4123 holding.
  • Barclays first reported a position in Monopar Therapeutics in Q1 2025 and has held it in 7 quarters since.
  • Barclays's Monopar Therapeutics position peaked at $1.37M in Q1 2026.
  • 106 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.